Wolfram syndrome, initially described in the first half of the 20th century, is a very rare genetic disorder that includes several clinical entities - juvenile-onset diabetes mellitus, diabetes insipidus, optic atrophy, and deafness, which is why the term DIDMOAD is sometimes used in the literature [1] [2] [3] [4] [5] [6] [7]. The onset of symptoms in Wolfram syndrome almost universally occurs in childhood and early adolescence [1] [3] [5]. Diabetes mellitus, with its typical symptoms of polyuria, polydipsia, weight loss, etc., is the first one to develop around 6 years of age, followed by atrophy of the optic nerve that presents with severe deficits in peripheral and color vision around 11 years of age [1] [2] [5]. Diabetes insipidus appears soon after, whereas a variable degree of sensorineural hearing deficit (from total hearing loss from birth to a delayed presentation of a milder impairment in adolescence that progressively worsens) has been observed [1] [2] [3]. Abnormalities of the urinary tract, such as atony of the bladder, ductal obstruction, and difficulties urinating affect up to 90% of patients and cause significant impairment in the quality of life [1] [2]. However, the main reason for a poor overall prognosis is the eventual occurrence of neurological deficits that presumably appear as a result of underlying genetic mutations - ataxia, myoclonus, dysphagia, poor autonomic system regulation (diarrhea, sweating, inability to control sphincters, etc.) reduced senses, psychiatric symptoms (mainly mood disorders), and atrophy of the brainstem that leads to respiratory insufficiency have all been documented [1] [2] [3]. Unfortunately, most patients die suffering from Wolfram syndrome at a median age of 30 years [1] [2] [3].

The diagnosis of Wolfram syndrome might be difficult to attain given the rare occurrence of this genetic disease, as studies estimate a prevalence rate of 1 in 160,000 to 770,000 individuals [1] [2]. For this reason, physicians must perform a detailed clinical examination and obtain a thorough patient history [1]. Because the autosomal recessive pattern of inheritance is established as the mode of transmission, a detailed family history might be of crucial importance for identifying similar symptoms in parents or other close relatives. Some authors claim that in all children under 16 years of age who present with diabetes mellitus and visual deficits, Wolfram syndrome must be included in the differential diagnosis [1] [5]. During the physical examination, which should include a comprehensive neurological assessment, as well as vision and hearing testing, key pieces of the clinical presentation can be revealed. To confirm the diagnosis, however, genetic testing for Wolfram syndrome 1 (WFS1) gene, located on chromosome 4, must be carried out [1] [3] [4]. The exact pathogenesis model remains unknown, but WFS1 is assumed to play a key role in the functioning of cells of both endocrine and neuronal origin [5]. In addition to WFS1 mutations, some studies have identified additional mutations that have shown autosomal dominant properties [4].

There is currently no cure for Wolfram Syndrome, and treatment focuses on managing symptoms and improving quality of life. Diabetes mellitus is treated with insulin therapy, while diabetes insipidus is managed with desmopressin, a synthetic hormone. Vision and hearing loss require supportive measures, such as visual aids and hearing devices. Regular monitoring and supportive therapies, including physical and occupational therapy, can help manage neurological and psychiatric symptoms. Multidisciplinary care involving endocrinologists, neurologists, ophthalmologists, and audiologists is often necessary.

The prognosis for individuals with Wolfram Syndrome varies depending on the severity and progression of symptoms. It is a progressive disorder, and most patients experience significant vision and hearing loss over time. Life expectancy is often reduced, with many individuals developing severe neurological complications. However, early diagnosis and comprehensive management can improve quality of life and delay the progression of symptoms.

Wolfram Syndrome is primarily caused by mutations in the WFS1 gene, which provides instructions for producing a protein called wolframin. This protein is involved in regulating calcium levels within cells and is essential for the normal functioning of various tissues, including the brain, pancreas, and eyes. Mutations in the WFS1 gene disrupt these processes, leading to the symptoms associated with Wolfram Syndrome. The condition is inherited in an autosomal recessive pattern, meaning both copies of the gene in each cell have mutations.

Wolfram Syndrome is a rare disorder, with an estimated prevalence of 1 in 500,000 to 1 in 1,000,000 people worldwide. It affects both males and females equally and has been reported in various ethnic groups. Due to its rarity, the syndrome is often underdiagnosed or misdiagnosed, which can delay appropriate management and support for affected individuals.

The pathophysiology of Wolfram Syndrome involves the dysfunction of the endoplasmic reticulum (ER), a cellular structure responsible for protein folding and calcium storage. Mutations in the WFS1 gene lead to ER stress and impaired calcium homeostasis, resulting in cell death, particularly in insulin-producing pancreatic beta cells, retinal ganglion cells, and neurons. This cellular dysfunction underlies the main features of the syndrome, including diabetes mellitus, optic atrophy, and neurological symptoms.

Currently, there are no specific measures to prevent Wolfram Syndrome, as it is a genetic condition. Genetic counseling is recommended for families with a history of the disorder to understand the risks and implications of passing the condition to offspring. Prenatal testing and preimplantation genetic diagnosis may be options for at-risk couples to consider.

Wolfram Syndrome is a rare genetic disorder characterized by a combination of diabetes mellitus, optic atrophy, diabetes insipidus, and hearing loss. It is caused by mutations in the WFS1 gene and is inherited in an autosomal recessive pattern. While there is no cure, early diagnosis and comprehensive management can improve quality of life for affected individuals. Multidisciplinary care is essential to address the diverse symptoms and complications associated with the syndrome.

If you or a loved one has been diagnosed with Wolfram Syndrome, it is important to understand that this is a complex condition requiring ongoing medical care. Regular check-ups with a team of specialists, including endocrinologists, neurologists, ophthalmologists, and audiologists, are crucial for managing symptoms and maintaining quality of life. Supportive therapies, such as insulin for diabetes and visual or hearing aids, can help manage daily challenges. Genetic counseling may be beneficial for understanding the condition and planning for the future.

1. Urano F. Wolfram Syndrome: Diagnosis, Management, and Treatment. Curr Diab Rep. 2016;16:6.
2. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet. 1995;346(8988):1458–1463.
3. Barrett TG, Bundey SE. Wolfram (DIDMOAD) syndrome. J Med Genet. 1997;34(10):838–841.
4. Hansen L, Eiberg H, Barrett T, et al. Mutation analysis of the WFS1 gene in seven Danish Wolfram syndrome families; four new mutations identified. Eur J Hum Genet. 2005;13(12):1275–84.
5. Naderian G, Ashtari F, Nouri-Mahdavi K, Sajjadi V. A Case of Wolfram Syndrome. J Ophthalmic Vis Res. 2010;5(1):53-56.
6. Medlej R, Wasson J, Baz P, et al. Diabetes mellitus and optic atrophy: a study of Wolfram syndrome in the Lebanese population. J Clin Endocrinol Metab. 2004;89(4):1656-1661.
7. Rohayem J, Ehlers C, Wiedemann B, et al. Diabetes and Neurodegeneration in Wolfram Syndrome: A multicenter study of phenotype and genotype. Diabetes Care. 2011;34(7):1503-1510.